A Derivative of Plumbagin Targets the JAK2/STAT3 Pathway to Inhibit the Progression of Oral Squamous Cell Carcinoma
Molecules · 09.07.2026 · 31 (14) · 2419
DOI: 10.3390/molecules31142419 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 09.07.2026. Verfasst von Xiyang Sun und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Biology, College of Pharmacy, Nankai University, Tianjin 300353, China. Hauptthemen laut MEDLINE: Naphthoquinones, STAT3 Transcription Factor, Janus Kinase 2, Mouth Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Science and Technology Project.
Abstract (Originalsprache)
Signal transducer and activator of transcription 3 (STAT3) drives multiple hallmarks of tumorigenesis, making it a validated therapeutic target for diverse cancers. The 1,4-naphthoquinones, such as plumbagin (PL), exhibit anticancer activity via inhibiting STAT3 phosphorylation and dimerization, but their severe cytotoxicity precludes clinical translation. Here, we screened 23 PL derivatives for STAT3 inhibitory activity and normal cell cytotoxicity, identifying III-1a as the optimal candidate with superior STAT3 inhibition and reduced toxicity compared to PL. Molecular docking and cellular thermal shift assay (CTESA) revealed that III-1a binds to the L244 residue within the coiled-coil domain (CCD) of STAT3. In vitro, III-1a dose-dependently suppressed JAK/STAT3 signaling in oral squamous cell carcinoma (OSCC), particularly STAT3 Ser727 phosphorylation. It inhibited STAT3-mediated epithelial—mesenchymal transition (EMT) and induced ferroptosis, thereby attenuating OSCC proliferation, invasion and migration. STAT3 knockdown abrogated its anti-tumor effects, and in vivo studies further confirmed its efficacy against OSCC growth. Collectively, this study identifies a novel PL-derived STAT3 inhibitor targeting STAT3 CCD to regulate EMT and ferroptosis, providing a promising therapeutic candidate for OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Biology, College of Pharmacy, Nankai University, Tianjin 300353, China.
- Tianjin Key Laboratory of Molecular Drug Research, College of Chemistry, Nankai University, Tianjin 300353, China.
- State Key Laboratory of Separation Membranes and Membrane Processes, School of Pharmaceutical Sciences, Tiangong University, Tianjin 300387, China.
- Tianjin Key Laboratory of Green Chemical Technology and Process Engineering, School of Pharmaceutical Sciences, Tiangong University, Tianjin 300387, China.
- Tianjin Key Laboratory of Structure and Performance for Functional Molecules, College of Chemistry, Tianjin Normal University, Tianjin 300387, China.
- Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China.
ORCID-Profile: Ziwen Wang, Honggang Zhou, Qingmin Wang
Förderung
- National Natural Science Foundation of China
- Tianjin Science and Technology Project
Zitieren
APA
Sun, X., He, Y., Xiao, T., Dong, Y., Tian, J., Wang, K., Ma, H., Wang, Z., Zhou, H., Wang, Q., & Yang, C. (2026). A Derivative of Plumbagin Targets the JAK2/STAT3 Pathway to Inhibit the Progression of Oral Squamous Cell Carcinoma. Molecules, 31(14), 2419. https://doi.org/10.3390/molecules31142419
Vancouver
Sun X, He Y, Xiao T, Dong Y, Tian J, Wang K, et al. A Derivative of Plumbagin Targets the JAK2/STAT3 Pathway to Inhibit the Progression of Oral Squamous Cell Carcinoma. Molecules. 2026;31(14):2419. doi:10.3390/molecules31142419
BibTeX
@article{Sun2026,
author = {Sun, Xiyang and He, Yiming and Xiao, Ting and Dong, Yuanmin and Tian, Jiao and Wang, Kaihua and Ma, Henan and Wang, Ziwen and Zhou, Honggang and Wang, Qingmin and Yang, Cheng},
title = {A Derivative of Plumbagin Targets the JAK2/STAT3 Pathway to Inhibit the Progression of Oral Squamous Cell Carcinoma},
journal = {Molecules},
year = {2026},
volume = {31},
number = {14},
pages = {2419},
doi = {10.3390/molecules31142419}
}
EUVIMED